Trial reportBMC psychiatry2009
Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia.
Trial report in BMC psychiatry, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Systematic Review of Real-World Treatment Patterns of Oral Antipsychotics and Associated Economic Burden in Patients with Schizophrenia in the United States.Advances in therapy · 2022Pooled it
- Switching antipsychotic medication to reduce sexual dysfunction in people with psychosis: the REMEDY RCT.Health technology assessment (Winchester, England) · 2020Trial
- Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study.CNS spectrums · 2014Trial
- Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia.BMC psychiatry · 2014Trial
- Cardiovascular risk management in patients using antipsychotics: a qualitative feasibility study.BJGP open · 2026Article
- Quantifying the Tolerability of Antipsychotic Treatment-Related Side Effects in Schizophrenia: A Survey Study of Patients and Caregiver Proxies.Patient preference and adherence · 2025Article
- Reasons for switching oral antipsychotic medications and related patterns of care and costs in patients with schizophrenia initiating monotherapy treatment: Claims-linked chart study.Journal of managed care & specialty pharmacy · 2024Observational
- Patterns of care and costs of switching oral antipsychotic medications in patients with schizophrenia initiating monotherapy treatment: A US claims analysis.Journal of managed care & specialty pharmacy · 2024Article
- Inpatient antipsychotic medication switching and rehospitalization risk among patients with schizophrenia-spectrum disorders.Schizophrenia research · 2024Article
- Predictors of antipsychotics switching among ambulatory patients with schizophrenia in Ethiopia: a multicenter hospital-based cross-sectional study.Annals of general psychiatry · 2024Article
- Treatment patterns among children and adolescents with attention-deficit/hyperactivity disorder in the United States - a retrospective claims analysis.BMC psychiatry · 2022Article
- Barriers to the management of sexual dysfunction among people with psychosis: analysis of qualitative data from the REMEDY trial.BMC psychiatry · 2022Article
- Atypical Treatment Switches in Schizophrenia Patients: Drivers and Associated Outcomes.Neuropsychiatric disease and treatment · 2022Article
- Switching Between Second-Generation Antipsychotics in Patients with Schizophrenia and Schizoaffective Disorder: 10-Year Cohort Study in Brazil.Frontiers in pharmacology · 2021Article
- Does knowledge of patient non-compliance change prescribing behavior in the real world? A claims-based analysis of patients with serious mental illness.ClinicoEconomics and outcomes research : CEOR · 2018Article
- Estimating the Value of New Technologies That Provide More Accurate Drug Adherence Information to Providers for Their Patients with Schizophrenia.Journal of managed care & specialty pharmacy · 2016Article
- Antipsychotic therapeutic drug monitoring: psychiatrists' attitudes and factors predicting likely future use.Therapeutic advances in psychopharmacology · 2015Article
- Switching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics: analysis of a Medicaid claims database.International clinical psychopharmacology · 2015Observational
- Antipsychotic dosing: found in translation.Journal of psychiatry & neuroscience : JPN · 2014Review
- An investigation of economic costs of schizophrenia in two areas of China.International journal of mental health systems · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSwitching between antipsychotic medications is common in the treatment of schizophrenia. However, data on clinical and economic outcomes from antipsychotic switching, in particular acute care service use, is fairly limited. The goal of this research was to assess the clinical and economic ramifications of switching antipsychotics during outpatient management of schizophrenia.
methodsData from a 1-year randomized, open-label cost-effectiveness study involving typical and atypical antipsychotics were assessed. The study protocol permitted switching of antipsychotics when clinically warranted. The risk of crisis-related events, use of acute-care services, and the time to the initial use of such services were determined in outpatients who switched antipsychotics compared with those who continued with their initial medications. Health care resource utilization data were abstracted from medical records and other sources (e.g., patient self-report), and direct costs were estimated using previously published benchmarks.
resultsAlmost one-third of patients (29.3%) underwent a switch from their initial antipsychotic agent, with an average duration of 100 days before such treatment alterations. Compared with their counterparts who remained on their initial therapies, individuals who switched antipsychotics experienced a significantly higher risk of acute-care services, including hospitalization (p = .013) and crisis services (p = .011). Patients undergoing medication switches also used acute-care services significantly sooner (p = .004) and accrued an additional $3,000 (a 25% increase) in annual total health care costs per patient, most of which was due to acute-care expenditures.
conclusionSwitching antipsychotic medications was found to be associated with considerably poorer clinical and economic outcomes, as reflected by, more frequent and more rapid use of acute-care services compared with persons remaining on their initial treatments.
trial registrationTrial ID 2325 in LillyTrials.com (also accessible via ClinicalStudyResults.org).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.